Page 14 - Anges Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Posted on 571 Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced today the first subjects have been dosed in a Phase 1 study of AV-001 in healthy subjects. AV-001 is a first-in-class therapeutic that targets the Tie2 tyrosine kinase receptor, a key regulatory protein in the vasculature responsible for maintaining normal vascular function. Should the benefit demonstrated in animal studies translate to the clinic, AV-001 has the potential to improve survival and shorten the duration of hospitalization ...

Vasomune Therapeutics Announces Initiation of the First-in-Human Clinical Trial of a Potential Vascular Normalization COVID-19 Treatment TORONTO--(Business Wire)--Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced today the first subjects have been dosed in a Phase 1 study of AV-001 in healthy subjects. AV-001 is a first-in-class therapeutic that targets the Tie2 tyrosine kinase receptor, a key regulatory protein in the vasculature responsible for maintaining normal vascular function. Should the benefit demonstrated in animal studies translate to the clinic, ...

Русский Tokyo, Dec. 16 (Jiji Press)--Shionogi & Co. started Wednesday a clinical trial to check the efficacy and safety of a novel coronavirus vaccine it is developing. The phase 1-2 trial will be joined by more than 200 adults, the Japanese drug maker said. It is the second coronavirus vaccine clinical trial in Japan after one launched by AnGes Inc., a biomedicine startup set up by an Osaka University professor. Shionogi's vaccine uses a genetically engineered antigen. During the trial, it will be administered to the participants twice with a three-week interval. The company will fol...

Japan’s development of COVID-19 vaccines is far behind that of global rivals. With the general public unlikely to have access to Japan-made vaccines until 2022, industry sources say reasons include a failure by the nation to address problems such as a lack of consolidation within the pharmaceutical industry and the sheltering of relatively small Japanese firms from international competition. This week the U.K. became the first Western country to begin inoculating its citizens with a commercially available COVID-19 vaccine. The same day, biotech startup AnGes Inc. — Japan’s front-runner,...